Key Highlights

  • Revenue of USD 183.5 million beat the USD 84.94 million estimate, and diluted Earnings were USD 0.58 per share.
  • GAAP Net Income was USD 60.1 million against a net loss of USD 64.5 million a year earlier.
  • Cash, cash equivalents and marketable securities totaled USD 430.0 million, and Operating Cash Flow was USD 38.4 million.
  • The company guided to full-year 2026 total Revenue of between USD 192 million and USD 194 million.

Freenome (NASDAQ:FRNM), a personalized cancer detection company that uses an AI-driven multiomics platform for blood-based tests, reported third quarter 2026 revenue of USD 183.5 million, above the USD 84.94 million estimate. Diluted Earnings per Share were USD 0.58 against an estimate of USD 0.14. The company attributed the revenue mainly to USD 180.0 million recognized under its collaboration and license agreement after FDA approval of SimpleScreen CRC.

Revenue was USD 1.0 million in the third quarter of 2025. License and collaboration revenue was USD 182.5 million, with none a year earlier, and service and other revenue was USD 0.9 million against USD 1.0 million.

FDA Approval and the License Agreement

The FDA approved SimpleScreen CRC on July 24, 2026. The company describes it as a blood-based screening test for adults 45 and older at average risk for colorectal cancer. The approval triggered a USD 100 million milestone payment under the collaboration and exclusive U.S. commercial license agreement with Exact Sciences, which Abbott assumed after its Acquisition of that company. The company also reported topline results from an updated version of the test.

Profit, Costs and Cash

GAAP net income was USD 60.1 million against a net loss of USD 64.5 million. Non-GAAP net income was USD 114.0 million against a non-GAAP net loss of USD 61.4 million, and adjusted EBITDA was USD 117.9 million against negative USD 56.3 million.

Total operating costs and expenses were USD 113.5 million against USD 66.3 million, an increase of USD 47.2 million that the company attributes primarily to transaction and stock-based compensation costs. Research and Development expense was USD 68.4 million and general and administrative expense was USD 44.6 million. The quarter also included an USD 11.6 million convertible note remeasurement loss.

Operating cash flow was USD 38.4 million and free cash flow was USD 35.7 million, against negative USD 42.0 million and negative USD 44.8 million a year earlier. Cash, cash equivalents and marketable securities were USD 430.0 million at September 30.

Public Listing, Notes and Guidance

The company began trading on the Nasdaq Capital Market on July 21, 2026, having raised approximately USD 310 million in gross proceeds. Roche's convertible note converted into about 6.4 million shares at USD 12.00 upon closing of the Business combination, and about USD 50.5 million of Abbott convertible note principal and interest converted into about 3.4 million shares at USD 15.00.

The company guided to full-year 2026 total revenue of USD 192 million to USD 194 million, reflecting license and collaboration agreements, research and development services and early commercial activities. The items to follow are commercial uptake, expense levels, cash use and guidance updates.